Investors in Twitter seem to be happy with the board of directors rebuffing Elon Musk’s $54.20/share bid for the company, driving the shares up 7.5% on 4/18 to $48.45, although the stock is still 10.6% below the $54.20/share offer which is currently on the table.
Although the board of directors of Twitter TWTR -4.7% Inc. didn’t outright reject Elon Musk’s $41.4 billion offer to buy the company, they did buy themselves some time by issuing a press release on Friday stating that the Board of Directors unanimously adopted a shareholder rights plan through April 14, 2023.
Also known as a “Poison Pill”, the Rights Plan gives existing shareholders the right to buy shares at the then-current exercise price, additional shares of common stock having a then-current market value of twice the exercise price of the right should Musk or anyone else buy shares on the open market consisting of 15% or more of Twitter’s outstanding stock without board approval.
However, Musk was likely expecting to be rebuffed and in fact said at a Ted Talk on Thursday that he has a “Plan B” if his offer is rejected. The Twitter Board is still reviewing the offer.
One potential plan would be to team up with three other friendly investors who could each buy 15% of the company and oust the board of directors. They could not act as a group, as the poison pill would kick in at that point, but if they were four different investors interested in a change of strategy for the company this could certainly be a strategy.
One potential investor in this scenario is Thoma Bravo LP, which is said to be running the numbers to see if they might make a competing bid to Musk’s. Other private equity companies are also kicking the tires. It’s unlikely that Musk would just walk away from making a play for Twitter after making such a bold move as he did on Thursday.
